Efficacy of Platelet-rich Plasma in Treatment of Melasma
NCT ID: NCT03674203
Last Updated: 2019-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
20 participants
INTERVENTIONAL
2017-05-01
2018-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Platelet Rich Plasma in Treatment of Melasma
NCT03308370
Efficacy of Intralesional PRP +/- Topical Silymarin in the Treatment of Melasma
NCT05626881
Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma
NCT04765930
Effects of RF Microneedle on Photoaging Skin
NCT05710068
Microneedle and Trichloroaceticacid in Treatment of Melasma
NCT03472235
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Sp-MELASQOL questionnaire, Fitzpatrick and MASI scales were applied, and photographs were taken with ambient light and with Wood's light with the Janus-II General Model. The patients were evaluated and classified, before and after the treatment by means of dermatoscopy, which was performed using a dermatoscope with polarized light (DermLite DL3N®), which allows an increase from 6 to 400X.
The dermatoscopy reported the findings of: Quantity, Density and Depth of melasma.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Application of platelet-rich plasma
The patients received three sessions of PRP application, at intervals of 15 days between each of them. It was applied by means of a 32G needle to introduce the PRP by means of superficial micro-injections via the mesotherapy technique (approximately 1.5-2.0 mm deep) and it was deposited in the papillary dermis of the rosotro.
Platelet-Rich Plasma
1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Platelet-Rich Plasma
1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of pregnancy with a time greater than 6 months
* Informed consent
Exclusion Criteria
* History of skin cancer
* History of liver, thyroid diseases
* With active acne lesions and traumatic lesions on the face
* PRP pre-treatmentPre-treatment for melasma with less than 6 months
* Hb values \<10 g / dL or platelet count \<105x109 / L
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Mexicano del Seguro Social
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CLOTILDE FUENTES OROZCO
PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clotilde Fuentes, pHD
Role: PRINCIPAL_INVESTIGATOR
Instituto Mexicano del Seguro Social
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Western Medical Center, Mexican Institute of Social Security
Guadalajara, Jalisco, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R-2015-1301-88.
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.